Xiong Hanchu, Zhao Wenhe, Wang Ji, Seifer Benjamin J, Ye Chenyang, Chen Yongxia, Jia Yunlu, Chen Cong, Shen Jianguo, Wang Linbo, Sui Xinbing, Zhou Jichun
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, China.
Oncotarget. 2017 Apr 11;8(15):25721-25735. doi: 10.18632/oncotarget.14891.
The RNA binding protein Lin28 is best known for the critical role in cell development, recent researches also have implied its oncogenic function in various human cancers, including breast cancer. Specifically, aberrant Lin28 participates in multiple pathological processes, such as proliferation, metastasis, radiotherapy and chemotherapy resistance, metabolism, immunity and inflammation as well as stemness. In this review, we summarize the let-7-dependent and let-7-independent mechanism regulated by Lin28, focusing on its relation with tumor hallmarks in breast cancer, and subsequently discuss our present knowledge of Lin28 to develop a molecular-based therapeutic strategy against breast cancer.
RNA结合蛋白Lin28在细胞发育中的关键作用最为人所知,最近的研究也暗示了其在包括乳腺癌在内的多种人类癌症中的致癌功能。具体而言,异常的Lin28参与多种病理过程,如增殖、转移、放疗和化疗耐药、代谢、免疫和炎症以及干性。在本综述中,我们总结了由Lin28调节的let-7依赖性和let-7非依赖性机制,重点关注其与乳腺癌肿瘤特征的关系,随后讨论我们目前对Lin28的认识,以制定基于分子的乳腺癌治疗策略。